68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT
about
Updates of prostate cancer staging: Prostate-specific membrane antigenEvaluation of 99mTc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapsePredictive factors of 18F-choline PET/CT positivity in patients with prostate cancer recurrence after radiation therapy: is the impact of PSA nadir underestimated?The phytological future of prostate cancer staging: PSMA-PET and the dandelion theory.Ultra-small superparamagnetic iron oxides for metastatic lymph node detection: back on the block.Impact of 68Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy.PET imaging of recurrent and metastatic prostate cancer with novel tracers.68 Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment.68Ga-prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Prostate Cancer Imaging: A Narrative Literature Review.Change in Salvage Radiotherapy Management Based on Guidance With FACBC (Fluciclovine) PET/CT in Postprostatectomy Recurrent Prostate Cancer.PSMA PET and Radionuclide Therapy in Prostate Cancer.Metal-Based PSMA Radioligands.68Ga-PSMA PET/CT imaging in recurrent prostate cancer: Where are we now?68Ga-PSMA PET/CT for the detection of bone metastasis in recurrent prostate cancer and a PSA level <2 ng/ml: Two case reports and a literature review.Initial single-centre Canadian experience with 18F-fluoromethylcholine positron emission tomography-computed tomography (18F-FCH PET/CT) for biochemical recurrence in prostate cancer patients initially treated with curative intentCirculating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer.Salvage lymph node dissection after 68Ga-PSMA or 18F-FEC PET/CT for nodal recurrence in prostate cancer patients.Current status of theranostics in prostate cancer.68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy - diagnostic performance and impact on therapeutic decision-making.99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer.(68) Ga-PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature.Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.Advances in prostate-specific membrane antigen PET of prostate cancer.68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning.Performance of 68Ga-PSMA PET/CT for Prostate Cancer Management at Initial Staging and Time of Biochemical Recurrence.[Significance of PSMA imaging in prostate cancer].Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI.Incremental value of 68-gallium-prostate-specific membrane antigen positron emission tomography/computed tomography in patients with abnormal prostate-specific antigen and benign transrectal ultrasound biopsy.PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives.Hybrid PET/MR: Updated Clinical Use and Potential Applications
P2860
Q28079444-ECF7D6EB-53EE-4CC6-ADBD-8EF672D5EE6DQ33668676-CE047BAE-4F79-49EF-AD8C-B9C0E93935C6Q37427275-25548DAC-A921-4184-A400-3166FCB70876Q38648799-C52D1AE1-C043-4D11-BC06-2DE06843D161Q38734277-6E5DC310-4058-40F9-8D91-28F12B074CF8Q38804450-E184CB4D-0C0D-4DDE-A74F-A3A3D03A442CQ38831029-CB0B6D07-E734-40DA-A091-E3F8C3154066Q38895102-88AAA6F3-8A46-4C77-B585-849F5A874907Q38952552-F3F2A7D0-58AF-4677-ADFF-F6068D9EF5E0Q38982759-836D43A1-837F-41AB-B117-C5C0DD044733Q39003089-F13F36C1-6F79-4F64-97B3-2660954EAED6Q39198527-D5BBBD72-F31F-46EE-89FE-526FDC2E1275Q39276928-39B57223-41B8-4216-821B-87A44271F068Q39419798-D5A45E90-FE86-4512-A7BB-5F8B10E36CBDQ41829682-9E485D01-474A-4EE0-89C0-F8E7F999AA35Q44453209-46DFBC7A-D945-40C2-8862-DD1C7B63BA33Q47115390-484974DB-BCE0-48B4-9767-8E5A0C9C1836Q47241139-48608931-D5B0-4061-8BBF-648CE86739A5Q47273452-231F98A6-3C85-4075-B38E-6BA003B04697Q47438555-F8377519-C714-4B32-859A-D49ADAD23E17Q47693515-871B86EC-D5AC-4209-BED3-604B0FFA5B51Q48226517-78E41B99-71D8-46F6-9116-C1C6132784B9Q49713199-58358436-F8D1-4FCE-94C1-B64E4F76EFF1Q50083626-D0DF88B2-D09C-4412-8D44-FD7EC88EC9C5Q50182743-7BD70A43-F3C9-482B-8927-5AFE1286CA35Q52937814-01C70310-5A73-47D5-982D-95B0EB3AAD50Q52940451-7F627924-7C99-4ADF-82DE-6D70BE35AEF2Q55112074-6C9BF8C4-AE98-49A0-8FA2-AA80BB1036C1Q55399763-0A7094ED-7D07-475B-968D-48FF9481FE91Q58109703-F82CA959-81D1-48ED-868A-CF8D8599FBA9
P2860
68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
68Ga-PSMA-PET/CT in Patients W ...... nd Negative 18F-Choline-PET/CT
@en
68Ga-PSMA-PET/CT in Patients W ...... d Negative 18F-Choline-PET/CT.
@nl
type
label
68Ga-PSMA-PET/CT in Patients W ...... nd Negative 18F-Choline-PET/CT
@en
68Ga-PSMA-PET/CT in Patients W ...... d Negative 18F-Choline-PET/CT.
@nl
prefLabel
68Ga-PSMA-PET/CT in Patients W ...... nd Negative 18F-Choline-PET/CT
@en
68Ga-PSMA-PET/CT in Patients W ...... d Negative 18F-Choline-PET/CT.
@nl
P2093
P2860
P50
P1476
68Ga-PSMA-PET/CT in Patients W ...... nd Negative 18F-Choline-PET/CT
@en
P2093
Christina Bluemel
Constantin Lapa
Domenico Rubello
Fränze Linke
Hans-Juergen Wester
Hubertus Riedmiller
Johannes Czernin
Ken Herrmann
Matthias Eiber
Samuel Samnick
P2860
P304
P356
10.1097/RLU.0000000000001197
P577
2016-03-11T00:00:00Z